Cohen & Steers

NEW YORK , Feb. 20, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the first quarter of 2025 in the amount of $0.62 per share of common stock, representing a 5.1% increase from the $0.59 per share dividend last quarter. The dividend is payable on March 13, 2025 to stockholders of record as of the close of business on March 3, 2025.» Mehr auf prnewswire.com

Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.» Mehr auf accessnewswire.com

Cohen & Steers (CNS) faces AUM declines due to asset depreciation in REITs and preferred shares amid persistent inflation affecting bond markets. This could be a portent for incoming outflows or inflow deceleration. At any rate, the macro changes don't favour long-duration asset ETFs that CNS focuses on. Despite positive net inflows, revenue growth was offset by rising expenses, resulting in flat EPS.» Mehr auf seekingalpha.com